相关实验视频

Updated: Jul 14, 2026

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

A Murine Pancreatic Islet Cell-based Screening for Diabetogenic Environmental Chemicals

Published on: June 25, 2018

胰腺脂酶抑制剂:虚拟查和机械分析

Yingao Zhai¹, Kunshan Wang¹, Zenghui Yu¹

¹College of Food Science and Engineering, Bohai University, Jinzhou 121013, China.

International journal of biological macromolecules

|April 19, 2025

概括

素,基因斯坦和纳灵宁通过竞争性和可逆机制有效抑制胰腺脂酶 (PL). 这些天然化合物显示出作为新的PL抑制剂的前景,Chrysin显示出最强的抑制作用.

科学领域:

生物化学生物化学
药理学药理学是指药理学的学科.
计算化学的计算化学

背景情况:

胰腺脂酶 (PL) 是饮食脂肪消化中的关键酶.
抑制PL可以帮助控制肥胖和相关的代谢障碍.
自然化合物为PL抑制提供了潜在的治疗策略.

研究的目的:

通过使用3D-QSAR药模型,选克莱辛 (Chr),基因斯坦 (Gen) 和纳灵宁 (Nar) 作为潜在的胰腺脂酶抑制剂.
阐明这些黄类药物抑制PL的详细机制.
评估Chr,Gen和Nar作为PL抑制剂的结合相互作用和疗效.

主要方法:

3D-QSAR药模拟用于虚拟查.
酶活性测定和动力学测试以确定抑制参数 (IC50,Ki).
多光谱技术 (光火,UV-Vis) 和分子对接用于相互作用分析.
分子动力学 (MD) 模拟以评估复杂的稳定性和结合的自由能量.

主要成果:

Chr,Gen 和 Nar 具有竞争性和可逆性抑制了不同强度的 PL (IC50 值: Chr < Gen < Nar).
确定了抑制常量 (Ki) 和结合常量 (Kb),表明了稳定的相互作用.
分子对接和MD模拟显示,化合物与活性部位 (Ser153-His264-Asp177) 附近结合,通过键,疏水力和范德瓦尔斯相互作用相互作用.
有约束力的自由能量分析证实了抑制顺序:Chr > Gen > Nar.

结论:

开发的3D-QSAR药模型准确地预测了Chr,Gen和Nar对PL的抑制潜力.
素,基因斯坦和纳灵宁是胰腺脂酶的有效抑制剂,为开发新型治疗剂提供了基础.
这些发现为合理设计和选天然来源的新型胰腺脂酶抑制剂提供了宝贵的见解.

关键词:

3D-QSAR 是一个3D-QSAR.模拟分子动力学模拟多光谱的多光谱的胰腺脂酶是一种胰腺脂酶.虚拟选是一个虚拟的选.

更多相关视频

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Screening Traditional Chinese Medicine Compounds for Inhibiting UCHL3 Activity Based on Molecular Docking and Deubiquitinating Enzyme Probe Technology

Published on: November 22, 2024

相关概念视频

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...